Médecine

Paramédical

Autres domaines


S'abonner

The PASE questionnaire: Pilot-testing a Psoriatic Arthritis Screening and Evaluation tool - 19/08/11

Doi : 10.1016/j.jaad.2007.04.001 
M. Elaine Husni, MD, MPH a, Kathryn H. Meyer, MS b, Darel S. Cohen, MD, MPH c, Elinor Mody, MD d, e, Abrar A. Qureshi, MD, MPH c, e,
a Departments of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio 
b Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 
c Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 
d Division of Allergy, Immunology and Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 
e Center for Skin and Related Musculoskeletal Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 

Reprint requests: Abrar A. Qureshi, MD, MPH, Assistant Professor, Harvard Medical School, Department of Dermatology, Brigham and Women’s Hospital, 45 Francis St, 221L, Boston, MA 02115.

Abstract

Background

Complications associated with psoriatic arthritis (PsA) may be prevented with early diagnosis and initiation of therapy. Up to one third of psoriasis patients may have PsA. There is a need to screen psoriasis patients early for symptoms of PsA.

Objective

To develop and validate a patient self-administered tool to screen psoriasis patients for signs and symptoms of inflammatory arthritis.

Methods

The questionnaire (PASE; Psoriatic Arthritis Screening and Evaluation) was developed using standardized methodology for the development of both functional and health-related instruments geared toward musculoskeletal diseases. A multidisciplinary team of dermatologists, rheumatologists, and patient focus groups were involved in the design of the questionnaire.

Results

A total of 69 participants with known psoriasis and PsA before the initiation of systemic therapy were screened with PASE after institutional review board approval. The average age was 51 years, and 51% of the participants were female. A total of 25% (17/69) were diagnosed with PsA in this study, and 37% (24/69) were diagnosed with osteoarthritis. Patients with concomitant PsA and osteoarthritis were excluded. PASE total scores ranged from 23 to 68 (possible range, 15-75). In patients with PsA, the median total score was 53 (25th and 75th percentiles, 49 and 63, respectively) and 39 (25th and 75th percentiles, 28 and 47) in non-PsA patients (P < .001). Median PASE total score for osteoarthritis patients was 43 (25th and 75th percentiles, 37 and 51) and significantly different to PsA patient total median scores (P = .002). Using receiver operator curves, we determined that PASE total score ≥47 was able to distinguish PsA from non-PsA patients with 82% sensitivity and 73% specificity.

Limitations

PASE is a screening tool for PsA and does not replace a comprehensive musculoskeletal evaluation by a rheumatologist.

Conclusion

The PASE questionnaire is a self-administered tool that can be used to screen for PsA among patients with psoriasis. PASE can distinguish between symptoms of PsA and osteoarthritis. A larger study is needed to validate PASE in dermatology clinics in the community.

Le texte complet de cet article est disponible en PDF.

Plan


 Supported by a grant from the Department of Dermatology, Brigham and Women’s Hospital (to A. A. Q.).
 Disclosure: Dr Qureshi is a consultant for and has spoken for Abbott, Amgen, and Genentech, and has had a limited consulting relationship with Centocor. Dr Mody is a speaker for Abbott, Amgen, and Genentech. Dr Husni is a consultant for Genentech and Amgen. Ms Meyer and Dr Cohen have no conflicts of interest to declare.


© 2007  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 57 - N° 4

P. 581-587 - octobre 2007 Retour au numéro
Article précédent Article précédent
  • Cutaneous infiltration by cancer
  • Joaquim Marcoval, Abelardo Moreno, Jordi Peyrí
| Article suivant Article suivant
  • Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: The effect of UVB dose and skin color
  • Laura A.G. Armas, Susan Dowell, Mohammed Akhter, Sowjanya Duthuluru, Christopher Huerter, Bruce W. Hollis, Richard Lund, Robert P. Heaney

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.